Takeda suffers another setback in its quest to expand myeloma drug’s reach — and blockbuster potential
Takeda has stumbled again in its quest to build up the blockbuster potential of its multiple myeloma drug Ninlaro. The pharma giant says the drug combined with dexamethasone failed to provide significant help for patients with rare cases of systemic light-chain amyloidosis, so now they’re scrapping the entire Phase III program.
The drug failed on the first primary endpoint on hematological responses, and researchers are throwing in the towel on organ deterioration and death, the second primary endpoint, with little expectation of success. The drug combo with dex was compared against a physician’s choice selection of dexamethasone plus either melphalan, cyclophosphamide, thalidomide, or lenalidomide; or dexamethasone alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
